Role of 2′,6′-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds
- 1 August 2010
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 18 (16) , 6024-6030
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Bi- or multifunctional opioid peptide drugsLife Sciences, 2010
- Evolution of the Bifunctional Lead μ Agonist/δ Antagonist Containing the 2′,6′-Dimethyl-l-tyrosine−1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid (Dmt−Tic) Opioid PharmacophoreACS Chemical Neuroscience, 2009
- Agonist vs Antagonist Behavior of δ Opioid Peptides Containing Novel Phenylalanine Analogues in Place of Tyr1Journal of Medicinal Chemistry, 2009
- Further Studies on Lead Compounds Containing the Opioid Pharmacophore Dmt-TicJournal of Medicinal Chemistry, 2008
- Role of benzimidazole (Bid) in the δ-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH2-Bid (UFP-502)Bioorganic & Medicinal Chemistry, 2008
- Effect of Lysine at C-Terminus of the Dmt-Tic Opioid PharmacophoreJournal of Medicinal Chemistry, 2006
- New 2‘,6‘-Dimethyl-l-tyrosine (Dmt) Opioid Peptidomimetics Based on the Aba-Gly Scaffold. Development of Unique μ-Opioid Receptor LigandsJournal of Medicinal Chemistry, 2006
- Selective Opioid DipeptidesBiochemical and Biophysical Research Communications, 1994
- A Convenient Asymmetric Synthesis of the Unnatural Amino Acid 2,6-Dimethyl-L-tyrosineSynthesis, 1992
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973